BOSTON--(BUSINESS WIRE)--Decibel Therapeutics, a clinical-stage biotechnology company developing novel therapeutics for hearing loss and balance disorders, today announced the appointment of Christine Poon to its board of directors.
Ms. Poon has spent more than 30 years in leadership roles in the biopharmaceutical industry. She currently serves as executive in residence of The Max M. Fisher College of Business at The Ohio State University, having retired from her role as dean of that institution in 2014. Prior to joining Fisher, Ms. Poon was vice chair and worldwide chair of pharmaceuticals at Johnson & Johnson, where she served on the company’s board of directors and executive committee and managed the company’s pharmaceutical businesses. Before Johnson & Johnson, she spent 15 years at Bristol-Myers Squibb, where her most recent position was president of international medicines. Ms. Poon currently serves on the board of directors of Regeneron Pharmaceuticals, Prudential Financial, Royal Philips Electronics and The Sherwin-Williams Company.
“It is a privilege and a pleasure to welcome such an extraordinary biopharmaceutical leader to the Decibel team,” said Steven Holtzman, president and chief executive officer of Decibel Therapeutics. “Chris’ extensive experience in commercial and international operations will be invaluable to Decibel as we advance our portfolio of small molecule, biologic and gene therapy programs and continue to build the leading hearing- and balance-focused biotechnology company.”
“Hearing and balance are fundamentally important to the human experience, yet there are no medications that can prevent deterioration or return function of these vital senses,” added Ms. Poon. “Decibel has assembled a unique platform designed to uncover the biological underpinnings of hearing and balance disorders and precision medicines that can improve the lives of millions of people. I’m thrilled to join Decibel’s board of directors and to contribute to its important mission.”
About Decibel Therapeutics, Inc.
Decibel Therapeutics, a clinical-stage biotechnology company, has established the world’s first comprehensive drug discovery, development and translational research platform for hearing and balance disorders. Decibel’s lead therapeutic candidate, DB-020, is designed to prevent hearing loss resulting from platinum-based chemotherapy. Decibel is also advancing a portfolio of discovery-stage programs aimed at restoring hearing and balance function to further our vision of a world in which the benefits and joys of hearing are available to all. Decibel is headquartered in Boston, Mass. For more information about Decibel Therapeutics, please visit www.decibeltx.com or follow @DecibelTx on Twitter.